Needham & Company
View Older Stories
-
Pre-Open Movers 07/21: (NBEV) (LXRX) (OMI) Higher; (ACAD) (PIRS) (CTSO) Lower (more...)
-
Lexicon Pharmaceuticals to Present at Upcoming Investor Conference
-
Lexicon Pharmaceuticals to Present at Upcoming Investor Conferences
-
Needham & Company Downgrades Lexicon Pharmaceuticals (LXRX) to Hold
-
Lexicon To Present At The 16th Annual Needham Healthcare Conference
-
Lexicon Pharma (LXRX): Xermelo Today And Lining Up Catalysts Throughout the Year - Needham
-
Needham and Company Reiterates Buy Rating and $21 PT on Lexicon Pharmaceutical (LXRX) Following FDA Approval of XERMELO
-
Needham & Company Reiterates Bullish View on Lexicon Pharmaceuticals (LXRX) Following Phase 3 Trial Results
-
Needham & Company Positive on Lexicon Pharma (LXRX) Following Sotagliflozin Phase 3 Data; Affirms at 'Buy'
-
Needham & Company Weighs in on Brexit Biotech Impact (ACAD) (GILD0 (ICPT) (SGEN)
-
Lexicon To Present At The 15th Annual Needham Healthcare Conference
-
Lexicon Pharmaceuticals (LXRX) Bullish Stance Reiterated at Needham & Company Following Positive Telotristat Phase 3 Results
-
Needham & Company Reiterates Buy Ahead of Lexicon Pharma (LXRX) Phase 3 Rsults
-
Lexicon To Present At Needham & Company's 14th Annual Healthcare Conference
-
Lexicon Pharma (LXRX) Prices $50M Common Stock Offering
-
Lexicon Pharma (LXRX) Reports $50M Stock Offering
-
Unusual 11 Mid-Day Movers 04/29: (OSH) (WRLS) (GALT) Higher; (LAS) (NTE) (GWAY) Lower
-
Unusual 11 Mid-Day Movers 12/31: (UNXL) (DUF) (LXRX) Higher; (EMITF) (CALM) (ZAZA) Lower
-
Unusual 11 Mid-Day Movers 10/12: (NINE) (GLUU) (NPSP) Higher; (AEZS) (OCZ) (TZOO) Lower
-
Pre-Open Movers 10/12: (LXRX) (IGTE) (STM) Higher; (AEZS) (AMD) (WFC) Lower (more...)
-
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Conference Call Takeaways
-
Needham & Company Maintains a 'Buy' on Lexicon Pharmaceuticals (LXRX); Big Pipeline Undervalued
-
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); LX4211 Phase 2b Trial Data Expected Soon
-
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); 2012 Preview: Several Key Clinical Milestones Anticipated
-
Needham & Company 2012 Biotech Preview
-
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Q3 Review
-
Needham & Company Maintains a 'Buy' on Lexicon Pharmaceuticals (LXRX); Underappreciated Given Number of Phase 2 Compounds Under Development
-
Needham & Company Reiterates a 'Buy' on Lexicon Pharmaceuticals (LXRX); Encouraging Phase 2 LX1032 Results in Sandostatin-Treated Carcinoid Syndrome Patients
-
Needham & Company Starts Lexicon Pharmaceuticals (LXRX) at Buy; Valuation is Attractive